| Drug General Information |
| Drug ID |
D0OH3J
|
| Former ID |
DNC009911
|
| Drug Name |
PD-0179483
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C26H25Cl2N5O3
|
| Canonical SMILES |
CCN(CCOC1=CC=C(C=C1)NC2=NC=C3C=C(C(=O)N(C3=N2)C)C4=C(C=<br />CC=C4Cl)Cl)C(=O)C
|
| InChI |
1S/C26H25Cl2N5O3/c1-4-33(16(2)34)12-13-36-19-10-8-18(9-11-19)30-26-29-15-17-14-20(25(35)32(3)24(17)31-26)23-21(27)6-5-7-22(23)28/h5-11,14-15H,4,12-13H2,1-3H3,(H,29,30,31)
|
| InChIKey |
ZPDSBOKGPBKXNQ-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Beta platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
|---|
| Basic fibroblast growth factor receptor 1 |
Target Info |
Inhibitor |
[1]
|
| Alpha platelet-derived growth factor receptor |
Target Info |
Inhibitor |
[1]
|
| Proto-oncogene tyrosine-protein kinase SRC |
Target Info |
Inhibitor |
[1]
|
| Lck tyrosine kinase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
PI3K-Akt signaling pathway
|
|
Focal adhesion
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
MicroRNAs in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04010:MAPK signaling pathway
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Proteoglycans in cancer
|
|
Central carbon metabolism in cancerhsa04010:MAPK signaling pathway
|
|
Endocytosis
|
|
Choline metabolism in cancerhsa04012:ErbB signaling pathway
|
|
Chemokine signaling pathway
|
|
VEGF signaling pathway
|
|
Tight junction
|
|
Platelet activation
|
|
GABAergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancerhsa04064:NF-kappa B signaling pathway
|
|
Osteoclast differentiation
|
|
Natural killer cell mediated cytotoxicity
|
|
T cell receptor signaling pathway
|
|
Primary immunodeficiency
|
|
NetPath Pathway
|
TCR Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
PDGF signaling pathwayP00005:Angiogenesis
|
|
FGF signaling pathwayP00005:Angiogenesis
|
|
Cadherin signaling pathway
|
|
Integrin signalling pathway
|
|
Parkinson disease
|
|
CCKR signaling map STP00049:Parkinson disease
|
|
T cell activation
|
|
Pathway Interaction Database
|
Signaling events mediated by PTP1B
|
|
Beta3 integrin cell surface interactions
|
|
S1P3 pathway
|
|
Nectin adhesion pathway
|
|
Signaling events mediated by TCPTP
|
|
SHP2 signaling
|
|
S1P1 pathway
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
PDGFR-beta signaling pathway
|
|
Validated targets of C-MYC transcriptional repression
|
|
PDGF receptor signaling networkglypican_1pathway:Glypican 1 network
|
|
Syndecan-4-mediated signaling events
|
|
N-cadherin signaling events
|
|
FGF signaling pathwayatf2_pathway:ATF-2 transcription factor network
|
|
PDGFR-alpha signaling pathway
|
|
PDGF receptor signaling networkendothelinpathway:Endothelins
|
|
Signaling events mediated by PRL
|
|
LPA receptor mediated events
|
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
Plasma membrane estrogen receptor signaling
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
EPHB forward signaling
|
|
Regulation of p38-alpha and p38-beta
|
|
CDC42 signaling events
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
Arf6 signaling events
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
Netrin-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
CXCR4-mediated signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Class I PI3K signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Regulation of Androgen receptor activity
|
|
E-cadherin signaling in the nascent adherens junction
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
ErbB1 downstream signaling
|
|
ErbB2/ErbB3 signaling events
|
|
EPHA forward signaling
|
|
E-cadherin signaling in keratinocytes
|
|
Nongenotropic Androgen signaling
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Syndecan-2-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
Syndecan-3-mediated signaling events
|
|
Ephrin B reverse signaling
|
|
Trk receptor signaling mediated by PI3K and PLC-gamma
|
|
EPHA2 forward signaling
|
|
Alpha-synuclein signaling
|
|
FGF signaling pathway
|
|
Alpha4 beta1 integrin signaling events
|
|
Signaling events mediated by focal adhesion kinasenfkappabatypicalpathway:Atypical NF-kappaB pathway
|
|
TCR signaling in naï
|
|
IL12-mediated signaling events
|
|
TCR signaling in naï
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
PIP3 activates AKT signaling
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
RAF/MAP kinase cascadeR-HSA-1257604:PIP3 activates AKT signaling
|
|
RAF/MAP kinase cascadeR-HSA-114604:GPVI-mediated activation cascade
|
|
Regulation of KIT signaling
|
|
Phosphorylation of CD3 and TCR zeta chains
|
|
Translocation of ZAP-70 to Immunological synapse
|
|
Generation of second messenger molecules
|
|
PECAM1 interactions
|
|
DAP12 signaling
|
|
CD28 co-stimulation
|
|
CD28 dependent PI3K/Akt signaling
|
|
CD28 dependent Vav1 pathway
|
|
CTLA4 inhibitory signaling
|
|
PD-1 signaling
|
|
Interleukin-2 signaling
|
|
WikiPathways
|
Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
Osteoblast Signaling
|
|
Focal Adhesion
|
|
PIP3 activates AKT signaling
|
|
PDGF Pathway
|
|
Signaling Pathways in Glioblastoma
|
|
Signaling by PDGFWP51:Regulation of Actin Cytoskeleton
|
|
Endochondral Ossification
|
|
Mesodermal Commitment Pathway
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Integrated Pancreatic Cancer Pathway
|
|
Neural Crest Differentiation
|
|
Signaling by FGFRWP51:Regulation of Actin Cytoskeleton
|
|
Hair Follicle Development: Organogenesis (Part 2 of 3)
|
|
Cardiac Progenitor Differentiation
|
|
Allograft Rejection
|
|
Signaling by PDGF
|
|
AngiogenesisWP673:ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Pregnane X Receptor pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL-3 Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Angiogenesis
|
|
Androgen receptor signaling pathwayWP61:Notch Signaling Pathway
|
|
Interferon type I signaling pathways
|
|
IL-2 Signaling Pathway
|
|
Inflammatory Response Pathway
|
|
Signaling by SCF-KIT
|
|
DAP12 interactions
|
|
Host Interactions of HIV factors
|
|
T-Cell Receptor and Co-stimulatory Signaling
|
|
B Cell Receptor Signaling Pathway
|
|
TCR signaling
|
|
Costimulation by the CD28 family
|
| References |
| REF 1 | Biochem Pharmacol. 2000 Oct 1;60(7):885-98.Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. |
|---|
